Cytosorbents (CTSO) Receivables - Other (2017 - 2026)

Cytosorbents (CTSO) has reported Receivables - Other for 10 consecutive years, with $6.9 million the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other rose 17.71% year-over-year to $6.9 million; the trailing twelve-month figure through Mar 2026 stood at $6.9 million (up 17.71% YoY), and the FY2025 full-year result was $7.1 million, up 27.23% from the prior year.
• Receivables - Other retreated to $6.9 million in Q1 2026 per CTSO's latest filing, from $7.1 million in the prior quarter.
• Across five years, Receivables - Other topped out at $7.1 million in Q4 2025 and bottomed at $3.2 million in Q1 2022.
• Historically, Receivables - Other has averaged $5.2 million across 5 years, with a median of $5.0 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Receivables - Other soared 38.65% in 2023, then rose 5.66% in 2024.
• Over 5 years, Receivables - Other stood at $3.8 million in 2022, then jumped by 38.65% to $5.3 million in 2023, then rose by 5.66% to $5.6 million in 2024, then increased by 27.23% to $7.1 million in 2025, then retreated by 3.16% to $6.9 million in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $6.9 million, $7.1 million, and $6.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.